Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection
HIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhib...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2014/472869 |
id |
doaj-22ab12f3912a4007a16c08e02432c893 |
---|---|
record_format |
Article |
spelling |
doaj-22ab12f3912a4007a16c08e02432c8932020-11-24T22:01:44ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/472869472869Computational Study to Determine When to Initiate and Alternate Therapy in HIV InfectionMatthias Haering0Andreas Hördt1Michael Meyer-Hermann2Esteban A. Hernandez-Vargas3Department of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyInstitut für Geophysik und extraterrestrische Physik, Technische Universität Braunschweig, Mendelssohnstraße 3, 38106 Braunschweig, GermanyDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyDepartment of Systems Immunology and Braunschweig Integrated Centre of Systems Biology, Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, GermanyHIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions.http://dx.doi.org/10.1155/2014/472869 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthias Haering Andreas Hördt Michael Meyer-Hermann Esteban A. Hernandez-Vargas |
spellingShingle |
Matthias Haering Andreas Hördt Michael Meyer-Hermann Esteban A. Hernandez-Vargas Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection BioMed Research International |
author_facet |
Matthias Haering Andreas Hördt Michael Meyer-Hermann Esteban A. Hernandez-Vargas |
author_sort |
Matthias Haering |
title |
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection |
title_short |
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection |
title_full |
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection |
title_fullStr |
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection |
title_full_unstemmed |
Computational Study to Determine When to Initiate and Alternate Therapy in HIV Infection |
title_sort |
computational study to determine when to initiate and alternate therapy in hiv infection |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2014-01-01 |
description |
HIV is a widespread viral infection without cure. Drug treatment has transformed HIV disease into a treatable long-term infection. However, the appearance of mutations within the viral genome reduces the susceptibility of HIV to drugs. Therefore, a key goal is to extend the time until patients exhibit resistance to all existing drugs. Current HIV treatment guidelines seem poorly supported as practitioners have not achieved a consensus on the optimal time to initiate and to switch antiretroviral treatments. We contribute to this discussion with predictions derived from a mathematical model of HIV dynamics. Our results indicate that early therapy initiation (within 2 years postinfection) is critical to delay AIDS progression. For patients who have not received any therapy during the first 3 years postinfection, switch in response to virological failure may outperform proactive switching strategies. In case that proactive switching is opted, the switching time between therapies should not be larger than 100 days. Further clinical trials are needed to either confirm or falsify these predictions. |
url |
http://dx.doi.org/10.1155/2014/472869 |
work_keys_str_mv |
AT matthiashaering computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection AT andreashordt computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection AT michaelmeyerhermann computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection AT estebanahernandezvargas computationalstudytodeterminewhentoinitiateandalternatetherapyinhivinfection |
_version_ |
1725838779878473728 |